Actively Recruiting
Evaluating How Drug and Placebo Affect Migraine Treatment Using Sumatriptan and Placebo Pills in Adults With Episodic Migraine
Led by University of Aarhus · Updated on 2026-04-13
128
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the interaction between drug and placebo responses in the treatment of acute migraine. This study focuses on patients with episodic migraine and aims to determine how treatment information affects adverse events. It uses an advanced balanced placebo design, which challenges traditional randomized controlled trials by varying the information given to patients about whether they receive an active drug or placebo. Participants will receive six treatment conditions in a randomized order during migraine attacks. They will take either an active drug, sumatriptan 100 mg, or an inactive placebo pill, while being told various information about the treatment they receive. All treatments and instructions are administered at home and include both correct and incorrect information about the medication. During the study, participants will report headache intensity and any adverse events before and two hours after taking each treatment. Additional assessments include mood, functional disability, rescue medication use, pain relief, and migraine symptoms. The study monitors blinding effectiveness and collects data on side effects and overall treatment response throughout the trial, which lasts until September 2028.
CONDITIONS
Brief Title
Trial Designs for Evaluating Migraine Treatment
Research Team
S
Sigrid Juhl Lunde, MSc, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here